Abstract: The present invention relates to compounds from Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection.

Abstract: The present invention relates to compounds from mycelium of Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) infection.

Abstract: The present invention relates to compounds from Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection.

Abstract: The present invention relates to compounds from Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection.

Abstract: The present invention relates to a compound derived from mycelium of Antrodia camphorata. The present invention also relates to the composition or mycelium comprising the compounds of the invention. The composition of the invention decreases systolic blood pressure and increases high density lipoprotein.

Abstract: The present invention relates to novel compounds from Antrodia cinnamomea and their use.

Abstract: The present invention relates to compounds from mycelium of Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) infection.

Abstract: The present invention relates to a compound derived from mycelium of Antrodia camphorata. The present invention also relates to the composition or mycelium comprising the compounds of the invention. The composition of the invention decreases systolic blood pressure and increases high density lipoprotein.

Abstract: The present invention relates to compounds from mycelium of Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) infection.

Abstract: The present invention relates to novel compounds from Antrodia cinnamomea and their use.

Abstract: The invention relates to polysaccharide extracted from Antrodia camphorata and the method for preparing the polysaccharide. The invention also relates to compositions and methods for hepatoprotective effect.

Abstract: The present invention relates to novel compounds from Antrodia camphorata and the use thereof.

Abstract: An antiviral preparation comprising as an active ingredient, a phorbol derivative of formula 1: wherein is R1 is —(CH2)aX(CH2)bCH3, —(CH2)cX(CH2)dYCH3, —CO(CH2)eCH3 or —(CH2)fCH3 R2 is —CO(CH2)nCH3, R3, R4 and R5 are hydrogen atom, or an aliphatic or aromatic carboxylic acid residue, X and Y are O or S, and each of a-f and n is a number, and having a specific safety index S.I.=CC50/EC50 of 10 or more wherein EC50 means a concentration at which HIV-1 induced cytopathogenic effect (CPE) in MT-4 cell is inhibited by 50%, and CC50 means a concentration at which survival of MT-4 cell in a cell proliferation test is reduced by 50%. These preparations are particularly effective for human immuno-deficiency virus (HIV).

Abstract: Disclosed is a method for producing an estrogen-like active intermediate (e.g., secoisolariciresinol) by culturing a lignan (e.g., a lignan derived from Eucommia ulmoides) together with a bacterium Lactobacillus acidophilus. Also disclosed a prophylactic/ameliorating agent for menopausal disorder and a functional beverage/food for preventing/ameliorating menopausal disorder comprising a lignan cultured together with a bacterium Lactobacillus acidophilus as an active ingredient.

Abstract: The present invention relates to novel compounds from Antrodia camphorata and the use thereof.

Abstract: The present invention relates to novel mixtures and maleic and succinic acid derivatives from mycelium of Antrodia camphorata and the medical use thereof. The present invention relates to the composition or mycelium comprising the compounds of the invention.

Abstract: The double blow molding process comprises a primary blow molding step of biaxially drawing and blow molding the preform into a primary intermediate product, a step of heating the primary intermediate product to shrink-mold it into the secondary intermediate product, and a secondary blow molding step of molding the secondary intermediate product into a bottle. This double blow molding process is characterized in that, just before the secondary blow molding step, the secondary intermediate product on standby is maintained at a temperature at least 40° C. or 50° C. higher than the mold temperature used in said secondary blow molding step. From such a temperature, it is possible to determine the double blow molding conditions, which can correspond to the levels of heat resistance required for the bottles, and to provide, with high productivity, the bottles having necessary levels of heat resistance.

Abstract: A synthetic resin container possessing a higher gas barrier property, and having a coating film (2) possessing a higher gas barrier property and positioned on an inner surface and/or and outer surface of the container body, wherein at least the coating film (2) is constituted of: an organic silicon compound layer (2a) positioned on the or each surface of the container body and including nitrogen, silicon, carbon, hydrogen, and oxygen; and a silicon oxide compound layer (2b) including a silicon oxide compound as a main component.

Abstract: A synthetic resin container possessing a higher gas barrier property, and having a coating film possessing a higher gas barrier property and positioned on an inner surface and/or outer surface of a body of the container, wherein the coating film (2) is constituted of a layered coating including at least a gas barrier coating (2a) and a cover coating (2b), the cover coating being positioned at a topmost side of the coating film. The cover coating (2b) includes a layer positioned at a topmost side of the cover coating and possessing such a water repellency that the layer has a contact angle with water of 80° to 100°. The layers (2a, 2b) constituting the coatings, respectively, are each formed by vapor deposition and each have a refractive index in a range of 1.3 to 1.6.

Abstract: An antiviral preparation comprising as an active ingredient, a phorbol derivative of formula 1: wherein is R1 —(CH2)aX(CH2)bCH3, —(CH2)cX(CH2)dYCH3, —CO(CH2)eCH3 or —(CH2)fCH3 R2 is —CO(CH2)nCH3, R3, R4 and R5 are hydrogen atom, or an aliphatic or aromatic carboxylic acid residue, X and Y are O or S, and each of a-f and n is a number, and having a specific safety index S.I.=CC50/EC50 of 10 or more wherein EC50 means a concentration at which HIV-1 induced cytopathogenic effect (CPE) in MT-4 cell is inhibited by 50%, and CC50 means a concentration at which survival of MT-4 cell in a cell proliferation test is reduced by 50%. These preparations are particularly effective for human immuno-deficiency virus (HIV).